Details of the Drug Combinations

General Information of This Drug (ID: DMP2BWX)

Drug Name

Ispinesib DMP2BWX

Synonyms

SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

Indication

Disease Entry	ICD 11	Status	REF
Head and neck cancer	2D42	Phase 2	[1]
Ovarian cancer	2C73	Phase 2	[1]
Renal cell carcinoma	2C90	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

24 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
(-)-englerin A + Ispinesib	DCDAEPR	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[2]
ABT-263 + Ispinesib	DC6EMN2	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[3]
Artemether + Ispinesib	DCEFUN6	Artemether	Ewing sarcoma (Cell Line: TC-71)	[2]
Bardoxolone methyl + Ispinesib	DC701U9	Bardoxolone methyl	Ewing sarcoma (Cell Line: TC-71)	[2]
Everolimus + Ispinesib	DCMAHMS	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[2]
Exherin + Ispinesib	DCN8AVV	Exherin	Ewing sarcoma (Cell Line: TC-71)	[2]
GDC-0084 + Ispinesib	DCHOSM1	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + GSK461364	DCM1B1N	GSK461364	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + Buparlisib	DCIUV2U	Buparlisib	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + Ruxolitinib	DC8DQEY	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[2]
Ispinesib + Everolimus	DC771QB	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + THAPSIGARGIN	DCNRLFG	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + Mitomycin	DCEIPSM	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
Ispinesib + TG100801	DCRZM3Q	TG100801	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + Romidepsin	DCZ1HJO	Romidepsin	Ewing sarcoma (Cell Line: TC-71)	[2]
Ispinesib + Ruxolitinib	DCK5Y88	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
Ispinesib + Ruxolitinib	DC7J0TH	Ruxolitinib	Hodgkin lymphoma (Cell Line: HDLM-2)	[3]
Lestaurtinib + Ispinesib	DC3KNKN	Lestaurtinib	Ewing sarcoma (Cell Line: TC-71)	[2]
MK-1775 + Ispinesib	DC65RBT	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[2]
NVP-AUY922 + Ispinesib	DC7MLR1	NVP-AUY922	Ewing sarcoma (Cell Line: TC-71)	[2]
Ombrabulin + Ispinesib	DC5BHYM	Ombrabulin	Ewing sarcoma (Cell Line: TC-71)	[2]
OSI-906 + Ispinesib	DCLX8Z6	OSI-906	Ewing sarcoma (Cell Line: TC-71)	[3]
Pelitinib + Ispinesib	DC6MNHW	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[2]
TG100801 + Ispinesib	DCYNLZO	TG100801	Ewing sarcoma (Cell Line: TC-71)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 24 DrugCom(s)

References

1	ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.